PreComb

PreComb is a Swiss biotech company that specializes in in vitro cancer diagnostics to advance cancer management. With its AI-guided technology, the privately held company focuses on developing personalized treatment solutions. In 2018, PreCombTherapeutics AG introduced its automated microtumor-based 3DTwin™ technology, providing clinical institutions the ability to integrate the innovation on-site in hospitals. This advancement allows for the functional evaluation of various cancer drugs, drug combinations, and drug concentrations directly on patient-derived micro-tumors, aiming to maximize treatment outcomes.

As of 04 October 2022, PreComb completed its Fr.1.30M Seed Round investment with backing from Kinled Holding Ltd and LongeVC. The company's innovative approach to precision medicine and cancer treatment holds promise for the healthcare and biotechnology sectors.

This groundbreaking development has significant implications for the biotechnology and healthcare industries, particularly in advancing personalized treatment and improving patient outcomes. With its headquarters in Switzerland, PreCombTherapeutics AG is at the forefront of pioneering AI-guided functional precision medicine, presenting an exciting venture for potential investors.